? GENOMICS SHARED RESOURCE (GSR) The mission of the GSR is to support OSUCCC members and high-impact cancer research projects with genomics expertise, instrumentation and centralized resources to generate high-quality data. The GSR is a state- of-the-art genomics laboratory that has substantially increased capacity through expansion to shared resources at Nationwide Children?s Hospital. The GSR has the following Specific Aims: 1) sequence DNA and RNA templates using both next generation sequencing platforms (i.e. Ilumina HiSeq4000 and NovaSeq6000) and capillary Sanger sequencing and genotyping (via ABI 3730XL DNA Analyzers); 2) use sensitive molecular hybridization methods to detect and quantify RNA transcript expression levels and structures such as splicing and/or DNA copy numbers and variation, including digital (NanoString) and microarray (Affymetrix) platforms; and 3) perform polymerase chain reaction (PCR)-based amplification to detect, quantify and confirm copy number variants, single nucleotide variants, gene expression, and small insertion/deletion polymorphisms including quantitative PCR (QuantStudio 12K flex) and high-throughput digital and custom PCR assay (BiomarkHD and Juno) technologies. In 2018, the GSR partnered with the Institute for Genomic Medicine (IGM) at Nationwide Children?s Hospital (NCH) to expand our next-generation sequencing (NGS) technology services. The GSR co-Directors are Drs. Amanda Toland (MCC) and Richard Wilson (CB). The GSR provides essential genomics expertise and instrumentation to members of all five programs. During the current funding cycle, the GSR contributed to 338 publications (63 > 10 impact factor) and 94 grants from members of all five programs. We have been highly responsive to changing technology and user needs and, as a result, we now offer Sanger sample pick-up, cell line verification, and single-cell (sc) RNA sequencing. We also regularly host technology- based seminars or workshops to introduce new technology to OSUCCC members. With OSUCCC and institutional support, we have expanded our facilities to improve sequencing capabilities and to include nanofluidics liquid handlers and library preparation systems for sc-sequencing to provide state-of-the-art resolution in cancer biology and response to therapy. In the next funding cycle, the GSR will support the genomics needs of all OSU strategic priorities. Given the robust OSUCCC recruitment, demand for services and new technologies will increase. The GSR will expand its staff, instrumentation and services before capacity is reached. New services under development include isolation of circulating tumor cells for down-stream culturing and genomic profiling, purchasing an instrument and developing protocols for spatial transcriptomics, purchasing an instrument for sc-DNA sequencing, and optimizing protocols for other sc-genomics and low-input NanoString applications. The annual budget of the GSR is $2,634,443, yet the CCSG request is $231,495. As such, the GSR leverages extensive institutional support and seeks only 8.8% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090011
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications